Novel adenine compound and use thereof

A topically administrable medicament containing an adenine compound represented by a general formula (1):

• wherein
• ring a is a 6 to 10 membered mono or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,
• n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,
• R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, r(s) may be the same or different,
• X1 is oxygen atom, sulfur atom, NR1 (wherein R1 is hydrogen atom or alkyl group) or a single bond,
• Y1 is a single bond, alkylene which may be substituted by oxo group, or divalent group of the formula below:
• (wherein r1 and r2 are independently an integer selected from 1 to 3),
• Y2 is a single bond, alkylene optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 or 2 oxygen atoms, or divalent group of the formula below:
• (wherein A′ is cycloalkylene, s1 is an integer selected from 1 to 3),
• Z is alkylene,
• Q1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents illustrated below,
• Q2 is a group selected from the group consisting of Substituents illustrated below,
• R10 or R11 in Q2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,
• when m is 0, Q1 is a group selected from the group consisting of Substituents illustrated below,
• Substituents:
• —COOR10;
• —COSR10;
• —OCOOR10;
• —OCOR10;
• —CONR11R12;
• —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may are taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s));
• and any group selected from the following formulas (3)˜(6):
• (wherein M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3),
• and when m is 2, (Y2-Q2)(s) may be the same or different,
• or a pharmaceutically acceptable salt thereof as an active ingredient.

A topically administrable medicament containing an adenine compound represented by a general formula (1):

• wherein
• Ring A is a 6 to 10 membered mono or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,
• n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,
• R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,
• X1 is oxygen atom, sulfur atom, NR1 (wherein R1 is hydrogen atom or alkyl group) or a single bond,
• Y1 is a single bond, alkylene which may be substituted by oxo group, or divalent group of the formula below:
• (wherein r1 and r2 are independently an integer selected from 1 to 3),
• Y2 is a single bond, alkylene optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 or 2 oxygen atoms, or divalent group of the formula below:
• (wherein A′ is cycloalkylene, s1 is an integer selected from 1 to 3),
• Z is alkylene,
• Q1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents illustrated below,
• Q2 is a group selected from the group consisting of Substituents illustrated below,
• R10 or R11 in Q2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,
• when m is 0, Q1 is a group selected from the group consisting of Substituents illustrated below,
• Substituents:
• —COOR10;
• —COSR10;
• —OCOOR10;
• —OCOR10;
• and —CONR11R12;
• wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R1 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may are taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s);
• and when m is 2, (Y2-Q2)(s) may be the same or different,
• or a pharmaceutically acceptable salt thereof as an active ingredient.